Product Disposal

Alliance Pharma PLC
03 November 2005


For Immediate Release                                            3 November 2005


                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                       Uniflu UK disposal raises £500,000

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has divested Uniflu, its cold and flu product,
for a one-off payment of £500,000.

Uniflu was acquired as part of the acquisition of Forceval, a prescription based
multi-vitamin for clinical malnutrition, in November 2004. The UK business for
Uniflu, as a consumer healthcare product, is non-core to Alliance, therefore the
company has taken the decision to divest the brand to G R Lane Health Products
Ltd based in Gloucester, UK, for a one-off payment of £500,000. Alliance retains
its Uniflu export business, with annual sales of £419,000 which is managed via
distributors.

Uniflu's presence in the UK market is underdeveloped compared with its position
in several other markets, particularly Lebanon where it is market leader in the
cold and flu segment.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:

'We have taken the decision to divest Uniflu for a one-off payment as the
product is  non-core to the Alliance Pharma business. We continue to retain the
export sales on Uniflu as that market is further developed and offers more value
going forward.'

For further information:
Alliance Pharma plc                                        + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich



Notes to editors



About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.

Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.


                      This information is provided by RNS
            The company news service from the London Stock Exchange